525 related articles for article (PubMed ID: 25504284)
21. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
[TBL] [Abstract][Full Text] [Related]
22. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
23. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
[TBL] [Abstract][Full Text] [Related]
24. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.
Antonescu CR; Romeo S; Zhang L; Nafa K; Hornick JL; Nielsen GP; Mino-Kenudson M; Huang HY; Mosquera JM; Dei Tos PA; Fletcher CD
Am J Surg Pathol; 2013 Mar; 37(3):385-92. PubMed ID: 23348204
[TBL] [Abstract][Full Text] [Related]
25. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
[TBL] [Abstract][Full Text] [Related]
26. Molecular research directions in the management of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052
[TBL] [Abstract][Full Text] [Related]
27. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
28. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
[TBL] [Abstract][Full Text] [Related]
29. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
30. [Gastrointestinal stromal tumors in neurofibromatosis type 1].
Bajor J
Orv Hetil; 2009 Jan; 150(4):149-53. PubMed ID: 19144598
[TBL] [Abstract][Full Text] [Related]
31. [Molecular and genetic features of gastrointestinal stromal tumors (GIST)].
Buleje S J; Yábar B A; Guevara-Fujita M; Fujita R
Rev Gastroenterol Peru; 2012; 32(4):394-9. PubMed ID: 23307090
[TBL] [Abstract][Full Text] [Related]
32. An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy.
Vassos N; Agaimy A; Schlabrakowski A; Hohenberger W; Schneider-Stock R; Croner RS
Virchows Arch; 2011 Mar; 458(3):363-9. PubMed ID: 21191613
[TBL] [Abstract][Full Text] [Related]
33. Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.
Farag S; van der Kolk LE; van Boven HH; van Akkooi ACJ; Beets GL; Wilmink JW; Steeghs N
Fam Cancer; 2018 Apr; 17(2):247-253. PubMed ID: 28710566
[TBL] [Abstract][Full Text] [Related]
34. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
Rutkowski P; Nowecki ZI; Debiec-Rychter M; Grzesiakowska U; Michej W; Woźniak A; Siedlecki JA; Limon J; vel Dobosz AJ; Kakol M; Osuch C; Ruka W
J Cancer Res Clin Oncol; 2007 Sep; 133(9):589-97. PubMed ID: 17458563
[TBL] [Abstract][Full Text] [Related]
35. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
36. Clinical implications of KIT and PDGFRA genotyping in GIST.
Martín-Broto J; Rubio L; Alemany R; López-Guerrero JA
Clin Transl Oncol; 2010 Oct; 12(10):670-6. PubMed ID: 20947481
[TBL] [Abstract][Full Text] [Related]
37. [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures].
Kong M; Wang YL; Xu LJ; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):617-20. PubMed ID: 20079191
[TBL] [Abstract][Full Text] [Related]
38. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours.
Wang C; Jin MS; Zou YB; Gao JN; Li XB; Peng F; Wang HY; Wu ZD; Wang YP; Duan XM
Scand J Gastroenterol; 2013 Sep; 48(9):1055-65. PubMed ID: 23862765
[TBL] [Abstract][Full Text] [Related]
40. Extra-gastrointestinal stromal tumor arising in the lesser omentum with a platelet-derived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review.
Kanamori K; Yamagata Y; Honma Y; Date K; Wada T; Hayashi T; Otsuki S; Sekine S; Yoshikawa T; Katai H; Nishida T
World J Surg Oncol; 2020 Jul; 18(1):183. PubMed ID: 32703220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
